NEWS
Amgen Pays $240m for Michigan Spinoff’s Dendritic Cell Targeting Molecules for Autoimmune Disorders
January 14, 2021
The multinational biopharmaceutical company Amgen has announced it will pay $240 million in upfront cash and milestone payments for molecules targeting autoimmune conditions from Ann Arbor, MI-based Evoq Therapeutics, a spinoff of research from the University of Michigan. Evoq, founded by Profs. Anna Schwendeman and James Moon, is named for the targeted dendritic cells the company uses to “evoke” immune tolerance in regulatory T cells.
Read more about the pair’s research and their new partnership with Amgen.
Latest News
U-M College of Pharmacy Honored with Prestigious Community Service Award
February 28, 2025
The College’s Community Health and Engagement team will accept the award at AACP’s Annual Meeting in July.
College of Pharmacy Unveils Brand New Website Focused on the Ultimate User Experience
February 27, 2025
The College of Pharmacy has launched a newly designed website aimed at enhancing user experience and telling the story of the College’s top-nationally ranked programs.
Circular RNA: An Emerging Class of RNA in the Fight Against Cancer and Infectious and Genetic Diseases
February 14, 2025
College of Pharmacy researchers in the lab of Guizhi (Julian) Zhu have developed a promising new weapon in the war on cancer: small circular mRNA vaccines.